RAF-MEK-ERK pathway in cancer evolution and treatment
Abstract The RAF-MEK-ERK signaling cascade is a well-characterized MAPK pathway
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …
involved in cell proliferation and survival. The three-layered MAPK signaling cascade is …
Prospects for combining targeted and conventional cancer therapy with immunotherapy
P Gotwals, S Cameron, D Cipolletta… - Nature Reviews …, 2017 - nature.com
Over the past 25 years, research in cancer therapeutics has largely focused on two distinct
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …
lines of enquiry. In one approach, efforts to understand the underlying cell-autonomous …
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Adoptive cell therapy represents a new paradigm in cancer immunotherapy, but it can be
limited by the poor persistence and function of transferred T cells. Here we use an in vivo …
limited by the poor persistence and function of transferred T cells. Here we use an in vivo …
MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade
PJR Ebert, J Cheung, Y Yang, E McNamara, R Hong… - Immunity, 2016 - cell.com
Targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) can induce
regression of tumors bearing activating mutations in the Ras pathway but rarely leads to …
regression of tumors bearing activating mutations in the Ras pathway but rarely leads to …
Overcoming immune evasion in melanoma
Melanoma is the most aggressive and dangerous form of skin cancer that develops from
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …
transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is …
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial
T Jiang, P Wang, J Zhang, Y Zhao, J Zhou… - … and Targeted Therapy, 2021 - nature.com
This multicenter phase-II trial aimed to investigate the efficacy, safety, and predictive
biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with …
biomarkers of toripalimab plus chemotherapy as second-line treatment in patients with …
4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
Clinical response to chimeric antigen receptor (CAR) T cell therapy is correlated with CAR T
cell persistence, especially for CAR T cells that target CD19+ hematologic malignancies. 4 …
cell persistence, especially for CAR T cells that target CD19+ hematologic malignancies. 4 …
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer …
HW Lee, W Chung, HO Lee, DE Jeong, A Jo, JE Lim… - Genome medicine, 2020 - Springer
Background Tumor cell-intrinsic mechanisms and complex interactions with the tumor
microenvironment contribute to therapeutic failure via tumor evolution. It may be possible to …
microenvironment contribute to therapeutic failure via tumor evolution. It may be possible to …
Rgs16 promotes antitumor CD8+ T cell exhaustion
N Weisshaar, J Wu, Y Ming, A Madi… - Science …, 2022 - science.org
T cells become functionally exhausted in tumors, limiting T cell–based immunotherapies.
Although several transcription factors regulating the exhausted T (Tex) cell differentiation are …
Although several transcription factors regulating the exhausted T (Tex) cell differentiation are …
Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial
The HERBY trial was a phase II open-label, randomized, multicenter trial evaluating
bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly …
bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly …